Key takeaways
A Wegovy plateau is when your weight loss significantly slows down despite continued use of Wegovy (semaglutide), even when maintaining your previous exercise and eating routine. Some people may even experience weight regain.
While increasing the dose of Wegovy may be beneficial for some people, doses above 7.2 mg weekly (in Wegovy HD) are generally not recommended. Always follow your provider’s instructions.
Adjusting your eating habits and exercise routine may help restart weight loss.
Here's what we'll cover
Here's what we'll cover
Here's what we'll cover
Key takeaways
A Wegovy plateau is when your weight loss significantly slows down despite continued use of Wegovy (semaglutide), even when maintaining your previous exercise and eating routine. Some people may even experience weight regain.
While increasing the dose of Wegovy may be beneficial for some people, doses above 7.2 mg weekly (in Wegovy HD) are generally not recommended. Always follow your provider’s instructions.
Adjusting your eating habits and exercise routine may help restart weight loss.
A Wegovy plateau can happen to anyone. You've been taking Wegovy (semaglutide) for a while, exercising and eating better, and you're losing weight.
Then, all of a sudden, it seems like you’re not quite shedding the pounds as fast as you had been. It may feel like you’re barely losing weight at all. What gives?
Welcome to what's known as the weight loss plateau. It's a common experience for many while losing weight, even when you're sticking to lifestyle changes such as eating plans and exercise or adhering to a treatment regimen with a medication such as Wegovy.
How to overcome a plateau while on Wegovy
Several strategies may help you overcome a weight loss plateau while taking Wegovy, including:
Add resistance training: Focus on short, consistent strength-building exercises to protect and maintain muscle mass. Research shows that losing muscle mass may reduce basal metabolic rate (BMR), which is the number of calories the body burns at rest. Building muscle through resistance training may help offset that effect.
Prioritize protein and fiber: Eat enough protein and fiber to help you feel full. Research suggests that protein and fiber both improve satiety, which is the feeling of fullness. When you feel fuller for longer, you may consume fewer calories overall.
Track your habits: Review your daily meals, liquid calories, steps, and overall activity levels to catch subtle changes in your routine. Tracking these details can also show whether your intake and activity still add up to a calorie deficit.
Limit alcohol consumption: Drinking alcohol on Wegovy may contribute to a plateau. Many alcoholic drinks are high in calories, which adds to overall intake, and alcohol may lead to more hunger and eating.
Talk to your healthcare provider: If a true plateau lasts four or more weeks, a healthcare provider, such as one on Ro, can discuss adjusting your dose or exploring other medical options. If you aren't on the highest dose (7.2 mg with Wegovy HD), a healthcare provider may consider raising it. You may also consider other GLP-1 medications.
Can a higher dose of Wegovy help with a plateau?
Yes, if you aren't on the highest dose of Wegovy, increasing your dose may help. The highest maintenance dosage of Wegovy is 7.2 mg once weekly (known as Wegovy HD). Wegovy HD is for adults who have tolerated the 2.4 mg dose for at least four weeks. Higher doses of semaglutide, the active ingredient in Wegovy, have not been studied, so it is not known whether they are safe or effective.
If you're already taking the highest dosage of Wegovy (7.2 mg once weekly), your healthcare provider may adjust your treatment plan to help address the plateau.
Ultimately, it "depends on the person and their goal," says Beverly Tchang, MD, an endocrinologist and Ro obesity medicine advisor. "For many people, losing just 5% of their weight is sufficient to achieve multiple health benefits, and Wegovy helps 9 out of 10 people achieve this goal."
These health benefits can include improved blood pressure, quality of life, and even sexual function (by improving symptoms of conditions such as erectile dysfunction).
There's also evidence that weight loss may improve symptoms of depression and lower the risk of heart attack or stroke. Additional benefits may come with more weight loss, including relief from obstructive sleep apnea and prediabetes.
When you start a weight loss journey, it's typical to lose more weight in the beginning. "In the clinical trials, people continued to lose weight throughout the first year of taking Wegovy, albeit more slowly in the second half of the year than the first half," Dr. Tchang says.
For example, in one study, people lost nearly 15% of their body weight over 68 weeks of taking Wegovy. In another two-year study, weight loss slowed and leveled off from about week 60 onward.
"Once you reach your goal weight, the hope is that the plateau lasts forever," Dr. Tchang says. "This means you're in the next phase: weight maintenance."
Avoid changing your Wegovy dosage without talking with a healthcare provider first.
Why does a weight loss plateau happen on Wegovy?
A Wegovy weight loss plateau happens when the body reaches a new equilibrium at a lower weight, influenced by changes in metabolism and hormones.
Plateaus are a normal part of weight loss journeys. As weight drops, metabolism adapts to the new eating and exercise routine and slows the body's energy use in what it perceives as a time of limited resources. Changing hormone levels play a role in this, too.
"Hormones in our body protect us from losing too much weight," Dr. Tchang says. "They cause the 'weight loss plateau' that everyone experiences, whether they are using diet, exercise, or medications."
The slowdown in metabolism during a weight loss plateau is part of the body's natural adaptation to weight loss, sometimes called starvation mode. You may be aiming for a healthier weight, but your hormones don't know that.
The body senses that less food is coming in, so it responds as if there's less access to food and resources, conserving energy stores such as body fat as a survival mechanism.
As part of the body's survival response, it's common for levels of ghrelin (the "hunger" hormone) to increase, while levels of leptin (the "satiety" hormone) decrease.
In addition to making people feel hungrier, these hormonal changes may cause fatigue, which can make staying physically active even harder.
While the goal is to lose fat, some people may lose too much lean muscle mass when they start losing weight, especially if they're not also taking steps to retain muscle through eating protein and strength training.
Losing weight gradually, while working to maintain and build muscle mass, may help counteract these effects and support metabolism.
What if I’m not losing weight on Wegovy
If you're not seeing the results you expected on Wegovy, there are steps that may help, whether weight loss has slowed or stalled. These strategies are a starting point.
1. Check in on your diet
Wegovy is approved for use along with a reduced-calorie eating plan and increased physical activity. In a clinical trial of Wegovy, participants were advised to reduce their intake by about 500 calories per day, but a healthcare provider may recommend something different for you depending on your starting weight and current calorie intake.
Small adjustments to eating habits may also help, according to research and clinical guidance on dietary approaches to weight loss. Options include:
Avoid sugary and processed foods
Drink less alcohol and sweetened beverages, or avoid them altogether
Eat smaller portions, more slowly
Limit snacking, especially late at night
Eat more vegetables, fruits, nuts, and whole grains
Increase your protein intake to build and preserve muscle
2. Refresh your exercise routine
In the same trial, participants were encouraged to get at least 150 minutes of moderate-intensity aerobic activity per week. For those who aren't getting much physical activity right now, starting with an activity you enjoy, such as walking for 20–30 minutes daily, can be a manageable first step.
If you're already exercising, you might try increasing to about 200 minutes per week. Research suggests this may lead to more weight loss and help prevent weight regain.
You may also want to consider whether your current workout mix is well suited to weight loss. Any kind of exercise can be beneficial, but research suggests that combining resistance training with aerobic exercise may be particularly effective at producing weight loss while preserving muscle mass.
The Physical Activity Guidelines for Americans recommend that adults do muscle-strengthening activities at least two days a week, in addition to at least 150 minutes per week of moderate-intensity aerobic activity. Muscle-strengthening activities include weight lifting, using resistance bands, or workouts that use body weight as resistance.
Make sure you are cleared for physical activity by your healthcare provider before making significant changes to your routine.
3. De-stress and relax
How are you feeling? Stress, sleep deprivation, or both may make weight loss more difficult.
Regularly sleeping fewer than seven hours per night can disrupt hormone levels, affect mood, and slow metabolism — any one of which may make it tougher to lose weight.
Sleep deprivation may also increase stress levels, which in turn may encourage the body to hold on to fat. Stress and sleepiness can also leave people feeling tired and less motivated, which may make it harder to stick to an eating plan and follow a workout routine.
If you could use more rest and relaxation (and who couldn't?), consider incorporating some of the following into your daily routine:
Adjusting your schedule to make room for more sleep (aim for approximately 7–9 hours each night)
Practicing deep breathing or progressive muscle relaxation exercises
Spending more time outside
Exploring guided imagery, visualization, or another type of meditation
Journaling
Aromatherapy
4. Work with your healthcare provider to adjust your dose
The highest dosage of the Wegovy injection is 7.2 mg once weekly, and the highest dosage of the Wegovy pill is 25 mg once daily. If you've been on a lower dose and aren't seeing the results you hoped for, you can ask your healthcare provider about increasing your dose.
Additionally, if you're on the Wegovy pill, you can ask your healthcare provider about switching to the Wegovy injection. The injection comes in a higher-dose version (Wegovy HD, 7.2 mg),than the pill.
5. Talk to your provider about switching medications
If Wegovy (semaglutide) isn't working as hoped, a healthcare provider will be able to discuss other weight loss medications with you.
For example, Zepbound (tirzepatide) is also approved by the US Food and Drug Administration (FDA) for weight management. Zepbound mimics two gut hormones (GLP-1 and GIP), while Wegovy only mimics one (GLP-1). One head-to-head trial suggests that tirzepatide is more effective for weight loss than semaglutide; however, this trial predates the newer 7.2 mg Wegovy HD dose.
Another option, especially for people who prefer a pill to an injection, is Foundayo (orforglipron), an oral GLP-1 medication that is FDA-approved for weight management. This pill is taken daily, with or without food, making it more flexible than the Wegovy pill, which requires you to wait 30 minutes before eating or drinking anything else.
6. Be patient
Progress with Wegovy takes time. As much as we might wish otherwise, weight loss is not linear, and there are ups, downs, and plateaus along the way. GLP-1 medications such as Wegovy also don't produce results overnight. It can take a few weeks to notice a reduction in hunger and approximately 4–12 weeks to see weight loss results.
Bottom line
Weight loss plateaus, including a Wegovy plateau, are a normal and common experience. Here's what to know:
A weight loss plateau happens when the body adjusts to a new equilibrium, and changing hormone levels play a role, too.
If you aren't already on the highest dose of Wegovy (7.2 mg in Wegovy HD) and are tolerating your current dose well, a healthcare provider may consider increasing your dose to help you get past the plateau.
Other ways to address a Wegovy plateau include increasing strength training, following an eating plan high in protein and fiber, tracking calorie intake and activity levels, limiting alcohol, managing stress, getting enough sleep, and talking with a healthcare provider, such as a Ro-affiliated healthcare provider, for more advice.
Frequently asked questions (FAQs)
What is a Wegovy plateau?
A Wegovy plateau is when your rate of weight loss slows down significantly even though you're still taking Wegovy. Nothing external seems to have changed, since you may still be exercising and eating as you were before, but weight loss slows or stalls anyway.
A Wegovy plateau is a lot like a typical weight loss plateau, with the key difference being that it occurs while the person is taking Wegovy to lose weight.
This plateau may be accompanied by other changes, including:
Increased hunger
Increased fatigue
Minor weight gain
How to break a plateau on Wegovy?
A Wegovy plateau may be overcome with a combination of dose adjustments and lifestyle changes. If you're tolerating your current dose and aren't yet on the highest dose of Wegovy (7.2 mg once weekly), ask your healthcare provider whether increasing it makes sense for you.
Additionally, lifestyle changes may help, including adding more strength training to help preserve muscle mass, following an eating plan high in protein and fiber to help you feel fuller for longer, tracking your calorie intake and activity levels, limiting alcohol, managing stress levels, and getting enough sleep.
Does Wegovy eventually stop working?
Wegovy doesn't necessarily stop working, but weight loss may level off over time. In one two-year study, some participants taking 2.4 mg of semaglutide once weekly experienced a plateau from week 60 onward.
How long should a plateau last in weight loss?
There’s no set amount of time a plateau “should” last. How long a weight loss plateau lasts varies from person to person. Because a plateau reflects the body adapting to weight loss, changes to eating habits, physical activity, sleep, and stress may all affect how long it lasts. A healthcare provider can help identify what may be contributing.
How long does a Wegovy plateau last?
The length of a Wegovy plateau varies. In one two-year study, weight loss leveled off from about week 60 onward while participants stayed on treatment, so a plateau on Wegovy can be long-lasting. How long it lasts may depend on whether a healthcare provider adjusts your dose and what lifestyle changes you make.
DISCLAIMER
If you have any medical questions or concerns, please talk to your healthcare provider. The articles on Health Guide are underpinned by peer-reviewed research and information drawn from medical societies and governmental agencies. However, they are not a substitute for professional medical advice, diagnosis, or treatment.
Wegovy Important Safety Information: Read more about serious warnings and safety info.
GLP-1 Important Safety Information: Read more about serious warnings and safety info.
Zepbound Important Safety Information: Read more about serious warnings and safety info.
Foundayo Important Safety Information: Read more about serious warnings and safety info.
References
Aronne, L. J., Horn, D. B., le Roux, C. W., et al. (2025). Tirzepatide as compared with semaglutide for the treatment of obesity. The New England Journal of Medicine, 393(1), 26–36. doi: 10.1056/NEJMoa2416394. Retrieved from https://pubmed.ncbi.nlm.nih.gov/40353578/
Cooper, C. B., Neufeld, E. V., Dolezal, B. A., et al. (2018). Sleep deprivation and obesity in adults: a brief narrative review. BMJ Open Sport & Exercise Medicine, 4(1), e000392. doi: 10.1136/bmjsem-2018-000392. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196958/
Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. doi: 10.1038/s41591-022-02026-4. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556320/
Guarneiri, L. L., Kirkpatrick, C. F., & Maki, K. C. (2025). Protein, fiber, and exercise: a narrative review of their roles in weight management and cardiometabolic health. Lipids in Health and Disease, 24(1), 237. doi: 10.1186/s12944-025-02659-7. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12255039/
Hewagalamulage, S. D., Lee, T. K., Clarke, I. J., et al. (2016). Stress, cortisol, and obesity: a role for cortisol responsiveness in identifying individuals prone to obesity. Domestic Animal Endocrinology, 56(Suppl), S112–S120. doi: 10.1016/j.domaniend.2016.03.004. Retrieved from https://pubmed.ncbi.nlm.nih.gov/27345309/
Kim, J. Y. (2021). Optimal diet strategies for weight loss and weight loss maintenance. Journal of Obesity & Metabolic Syndrome, 30(1), 20–31. doi: 10.7570/jomes20065. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017325/
Leidy, H. J., Clifton, P. M., Astrup, A., et al. (2015). The role of protein in weight loss and maintenance. The American Journal of Clinical Nutrition, 101(6), 1320S–1329S. doi: 10.3945/ajcn.114.084038. Retrieved from https://www.sciencedirect.com/science/article/pii/S0002916523274274
Parmar, R. M. & Can, A. S. (2023). Dietary approaches to obesity treatment. StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK574576/
Ryan, D. H. & Yockey, S. R. (2017). Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. Current Obesity Reports, 6(2), 187–194. doi: 10.1007/s13679-017-0262-y. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497590/
Sarwan, G. & Rehman, A. (2022). Management of weight loss plateau. StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK576400/
Strasser, B. (2013). Physical activity in obesity and metabolic syndrome. Annals of the New York Academy of Sciences, 1281(1), 141–159. doi: 10.1111/j.1749-6632.2012.06785.x. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3715111/
Swift, D. L., Johannsen, N. M., Lavie, C. J., et al. (2014). The role of exercise and physical activity in weight loss and maintenance. Progress in Cardiovascular Diseases, 56(4), 441–447. doi: 10.1016/j.pcad.2013.09.012. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3925973/
Traversy, G. & Chaput, J. P. (2015). Alcohol consumption and obesity: an update. Current Obesity Reports, 4(1), 122–130. doi: 10.1007/s13679-014-0129-4. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC4338356/
Trexler, E. T., Smith-Ryan, A. E., & Norton, L. E. (2014). Metabolic adaptation to weight loss: implications for the athlete. Journal of the International Society of Sports Nutrition, 11(1), 7. doi: 10.1186/1550-2783-11-7. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943438/
U.S. Department of Health and Human Services (HHS). (2018). Physical Activity Guidelines for Americans, 2nd Edition. Retrieved from https://odphp.health.gov/sites/default/files/2019-09/Physical_Activity_Guidelines_2nd_edition.pdf
U.S. Food and Drug Administration (FDA-a). (2026). Highlights of Prescribing Information: Foundayo (orforglipron) Tablets, for Oral Use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934s003lbl.pdf
U.S. Food and Drug Administration (FDA-b). (2026). Highlights of Prescribing Information: Wegovy (semaglutide) Injection, for Subcutaneous Use; Wegovy (semaglutide) Tablets, for Oral Use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf
U.S. Food and Drug Administration (FDA-c). (2026). Highlights of Prescribing Information: Zepbound (tirzepatide) Injection, for Subcutaneous Use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf
Watson, N. F., Badr, M. S., Belenky, G., et al. (2015). Recommended amount of sleep for a healthy adult: a joint consensus statement of the American Academy of Sleep Medicine and Sleep Research Society. Sleep, 38(6), 843–844. doi: 10.5665/sleep.4716. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC4434546/
Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002. doi: 10.1056/NEJMoa2032183. Retrieved from https://www.nejm.org/doi/10.1056/NEJMoa2032183














